These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27477035)

  • 1. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis.
    Tanaka Y; Mori T; Ito F; Koshiba A; Kusuki I; Kitawaki J
    Int J Gynaecol Obstet; 2016 Nov; 135(2):135-139. PubMed ID: 27477035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
    Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T
    Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study.
    Takeda T; Kondo A; Koga S; Hayakawa J; Hayakawa K; Hiramatsu K; Yaegashi N
    J Obstet Gynaecol Res; 2015 Oct; 41(10):1584-90. PubMed ID: 26310836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
    Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life in Japanese Patients with Dysmenorrhea or Endometriosis-Associated Pelvic Pain Treated with Extended Regimen Ethinylestradiol/Drospirenone in a Real-World Setting: A Prospective Observational Study.
    Yoshino O; Suzukamo Y; Yoshihara K; Takahashi N
    Adv Ther; 2022 Nov; 39(11):5087-5104. PubMed ID: 36053449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial.
    Harada T; Kosaka S; Elliesen J; Yasuda M; Ito M; Momoeda M
    Fertil Steril; 2017 Nov; 108(5):798-805. PubMed ID: 28911925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
    Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
    Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg.
    Mabrouk M; Solfrini S; Frascà C; Del Forno S; Montanari G; Ferrini G; Paradisi R; Seracchioli R
    Gynecol Endocrinol; 2012 Jun; 28(6):451-4. PubMed ID: 22132832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.
    Harada T; Momoeda M; Taketani Y; Hoshiai H; Terakawa N
    Fertil Steril; 2008 Nov; 90(5):1583-8. PubMed ID: 18164001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
    Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
    Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea.
    Uysal G; Akkaya H; Cagli F; Tutus S; Tayyar AT
    J Obstet Gynaecol; 2018 Aug; 38(6):828-832. PubMed ID: 29537325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
    Marr J; Heinemann K; Kunz M; Rapkin A
    Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.